Autopsy report · NCT03292653
Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure
Cause of deathOther
“1st two cohorts provided the required data, therefore 3rd cohort was not deemed necessary”
Life of this trial
- Registered 2 months before it started.
- Ran for about 1 year 8 months before it stopped.
- 32 participants enrolled.
- Results were posted on the registry 1 year 9 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Lexicon Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Cardiac Failure Aggravated
- Interventions
- Sotagliflozin; Placebo
- Participants
- 32
- Sites
- 6
- Countries
- Canada, Netherlands, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.